Is Response to OROS-Methylphenidate Treatment Moderated by Treatment with Antidepressants or Psychiatric Comorbidity? A Secondary Analysis from a Large Randomized Double Blind Study of Adults with ADHD

CNS Neuroscience and Therapeutics

Volumn 18, Issue 2, 2012, Pages 126-132

  Biederman, Joseph ^a,b   Mick, Eric ^a,b   Spencer, Thomas ^a,b   Surman, Craig ^a,b   Faraone, Stephen V ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

ADHD; Adult; Comorbidity; Methylphenidate; Moderators; Pharmacotherapy

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; FLUOXETINE; METHYLPHENIDATE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE;

ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; COMORBIDITY; DEPRESSION; DISEASE EXACERBATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PSYCHOPHARMACOTHERAPY; SUBSTANCE ABUSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMORBIDITY; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MENTAL DISORDERS; METHYLPHENIDATE; MIDDLE AGED; OSMOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856806918     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00233.x     Document Type: Article

References (33)

1. Barkley RA, Murphy KR, Fischer M. ADHD in Adults: What the Science Says. New York, NY: Guilford Press, 2008.
2. Faraone SV, Biederman J. Functional impairments in adult ADHD implications for diagnosis. 158th Annual meeting of the American Psyciatric Association: 2005, Atlanta, GA: American Psychiatric Association, 2005;36 p.
3. Faraone SV. Genetics of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:303-321.
4. Kessler R, Adler L, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: Results from the national comorbidity survey replication. Biol Psychiatry 2005;57:1442-1451.
5. Kessler RC, Adler L, Ames M, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med 2005;47:565-572.
6. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: Results from the national comorbidity survey replication. Am J Psychiatry 2006;163:716-723.
7. Biederman J, Faraone SV. The effects of attention-deficit hyperactivity disorder on employment and house hold income. Medscape General Medicine 2006;8:12.
8. Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J Atten Disord 2005;9:384-391.
9. Neale BM, Lasky-Su J, Anney R, et al. Genome-wide association scan of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1337-1344.
10. Seidman LJ. Neuropsychological functioning in people with ADHD across the lifespan. Clin Psychol Rev 2006;26:466-485.
11. Valera E, Faraone SV, Murray K, Seidman LJ. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry 2007;61:1361-1369.
12. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010;71:754-763.
13. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention deficit hyperactivity disorder. J Clin Psychopharmacol 2004;54:24-29.
14. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:456-463.
15. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS-methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006;59:829-835.
16. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008;63:981-989.
17. Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007;61:1380-1387.
18. Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, Biederman J. Double-blind, placebocontrolled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008;69:1364-1373.
19. Biederman J, Petty CR, Monuteaux MC, Mick E, Clarke A, Ten Haagen K, Faraone SV. Familial risk analysis of the association between attention-deficit/hyperactivity disorder and psychoactive substance use disorder in female adolescents: A controlled study. J Child Psychol Psychiatry 2009;50:352-358.
20. Biederman J, Petty CR, Wilens TE, et al. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry 2008;165:107-115.
21. Faraone SV, Wilens TE, Petty C, Antshel K, Spencer T, Biederman J. Substance use among ADHD adults: Implications of late onset and subthreshold diagnoses. Am J Addict 2007;16(Suppl 1):24-32;quiz 3-4.
22. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders-clinician version (SCID-CV). Washington, DC: American Psychiatric Press, 1997.
23. Orvaschel H. Schedule for affective disorder and schizophrenia for school-age children epidemiologic version, 5th ed. Ft. Lauderdale: Nova Southeastern University, Center for Psychological Studies, 1994.
24. National Institute of Mental Health. CGI (clinical global impression) scale: NIMH. Psychopharmacol Bull 1985;21:839-844.
25. Adler LA, Spencer T, Faraone SV, Kessler RC, Howes M, Biederman J. Validity of pilot adult ADHD self report scale (ASRS) to rate adult ADHD symptoms. Ann Clin Psychiatry 2006;18:145-148.
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
27. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
28. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV, 4th ed., Washington, DC: American Psychiatric Association, 1994.
29. StataCorp. Stata statistical software: Release 10. College Station, TX: StataCorp LP, 2007.
30. Biederman J, Mick EO, Surman C, et al. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry 2007;7:49.
31. Biederman J, Ball SW, Monuteaux MC, et al. New insights into the comorbidity between ADHD and major depression in adolescent and young adult females. J Am Acad Child Adolesc Psychiatry 2008;47:426-434.
32. Gadow KD, Nolan EE, Sverd J, Sprafkin J, Schwartz J. Anxiety and depression symptoms and response to methylphenidate in children with attention-deficit hyperactivity disorder and tic disorder. J Clin Psychopharmacol 2002;22:267-274.
33. Murphy P, Schachar R. Use of self-ratings in the assessment of symptoms of attention deficit hyperactivity disorder in adults. Am J Psychiatry 2000;157:1156-1159.